Infectious Disease

Imatinib yields sustained clinical benefit in patients with hypoxemic COVID-19

Source/Disclosures

sources:

Schippers J, et al. D17: Top Knowledge in COVID. Presented at: American Thoracic Society International Conference; May 13-18, 2022; San Francisco (hybrid meeting).

Disclosures:
Schippers reports no relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Treatment with imatinib resulted in a sustained clinical benefit after 90 days in hospitalized patients with hypoxemic COVID-19, according to results of the CounterCOVID study.

At the American Thoracic Society International Conference, Job R. Schippers, MD-PhD candidate for pulmonary medicine at Amsterdam University Medical Center, presented long-term clinical outcomes at 90 days after treatment with imatinib.

Source: Adobe Stock.

Imatinib is a tyrosine kinase inhibitor that is currently used as an oncology drug to block an abnormal protein that signals cancer cells, according to an ATS press release.

“Imatinib was considered as a therapeutic option when it became evident that patients with severe COVID-19 had CT scan abnormalities suggestive of pulmonary edema … as a result of vascular leakage,” Schippers said in the release.

Results of a recent clinical trial demonstrated a benefit of imatinib treatment over 28-day follow-up in patients with hypoxemic COVID-19, with the greatest improvement in critically ill patients, according to the researchers.

Researchers evaluated longer-term clinical outcomes in 385 patients hospitalized with COVID-19. Patients were randomly assigned to imatinib (n=197) or placebo (n=188) for 10 days. Long-term outcomes included 90-day mortality, duration of invasive ventilation, ventilator-free days, length of ICU admission, length of hospital admission and ventilatory parameters.

At 90 days, 9.1% of patients who received imatinib and 16.5% of patients who received placebo died (HR = 0.53; 95% CI, 0.29-0.94; P = .03), according to the abstract. This result remained significant after the researchers adjusted for baseline imbalances including sex, obesity, diabetes and heart disease (HR = 0.52; 95% CI, 0.28-0.99; P = .045), according to the abstract.

The median number of ventilator-free days was 84 for patients in the ICU who received imatinib compared with 64 days for those who received placebo (P = .036) and median duration of invasive ventilation was 7 days compared with 12 days, respectively (P = .026), according to the abstract.

Mean length of ICU stay was 9 days in the imatinib group compared with 15 days in the placebo group (P = .098) and mean duration of hospitalization was 7 days compared with 6.5 days, respectively (P = .66).

Patients who were intubated and treated with imatinib had a significantly better longitudinal FiO2 course (P < .0001), the researchers reported in the abstract.

According to the researchers, the clinical benefit observed at 90 days may be explained by the improvement in oxygenation parameters.

References:

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

American Thoracic Society International Conference

American Thoracic Society International Conference

Related Articles